Actively Recruiting
The Effect of Allopurinol on the Risk of Cardiovascular Events in Patients with Cardiovascular Risk
Led by Poznan University of Medical Sciences · Updated on 2025-01-06
1116
Participants Needed
1
Research Sites
256 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Numerous studies, but not all, have suggested a positive effect of allopurinol on the cardiovascular system. The ALL-VASCOR study aims to evaluate the efficacy of allopurinol therapy for improving cardiovascular outcomes in patients at high and very high cardiovascular risk, excluding ischemic heart disease. This is particularly important due to the high cost of cardiovascular disease treatment and its status as one of the leading causes of death.
CONDITIONS
Official Title
The Effect of Allopurinol on the Risk of Cardiovascular Events in Patients with Cardiovascular Risk
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 40 and 70 years old
- Provided informed consent to join the study
- Serum uric acid levels above 5 mg/dL within six months before screening
- Meet at least one high or very high cardiovascular risk criterion including 10-year cardiovascular mortality risk over 2.5% (under 50 years) or 5% (50 years and older), documented cardiovascular diseases excluding ischemic heart disease, or diabetes/hypertension with organ damage such as vascular stiffness, left ventricular hypertrophy, increased urine albumin-creatinine ratio, or low ankle-brachial index
You will not qualify if you...
- Currently taking allopurinol, febuxostat, or other uric acid lowering drugs
- Contraindications to allopurinol
- Pregnant, breastfeeding, or planning pregnancy during the study
- Using hormone therapy containing estrogens
- Active cancer or cancer in the past five years (except locally malignant tumors)
- Uncontrolled hypertension with blood pressure ≥180/110 mmHg despite treatment
- Renal insufficiency with eGFR below 45 ml/min/1.73m2
- Untreated thyroid disorders
- Confirmed coronary artery disease
- Heart failure in NYHA class III or IV
- Taking azathioprine, mercaptopurine, or cyclosporin
- Participation in another clinical trial within the last three months or five half-lives of that treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Poznan University of Medical Sciences
Poznan, Wielkopolska, Poland, 60-355
Actively Recruiting
Research Team
P
Paweł Uruski, MD PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here